Prospective Single Blinded Randomized Controlled Trial Comparing The Covidien EEA™ Hemorrhoid and Prolapse Stapling Set With DST Series™ Technology Vs. Ethicon PPH03 In A Hemorrhoidopexy Procedure (HEMOSTASIS)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Medtronic - MITG
- Enrollment
- 149
- Locations
- 1
- Primary Endpoint
- Intraoperative Bleeding
Study Overview
Brief Summary
The purpose of this study is to demonstrate that the Covidien EEA™ Hemorrhoid and Prolapse Stapling Set for the treatment of hemorrhoids is non-inferior to the competitor device based on the primary endpoint.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to 85 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •The subject is able to understand and sign Informed Consent Form
- •The subject is between 18-85 years of age.
- •The subject has (symptomatic) Grade 2-3 Hemorrhoids and is eligible for stapled hemorrhoidopexy
Exclusion Criteria
- •The procedure is needed as revision hemorrhoid surgery.
- •Any female patient, who is pregnant, suspected pregnant, or nursing.
- •The participant has an active or a history of infection requiring antibiotics at the intended operative site within thirty (30) days prior to the planned surgery date.
- •The participant is unable or unwilling to comply with the study requirements, follow-up schedule.
- •The participant has a 1 year history of drug or alcohol abuse.
- •The participant has a history of venous thrombosis or pulmonary embolism.
- •The participant has a history of coagulopathy.
- •The participant has taken aspirin, anti-coagulation and/or anti platelet therapies (e.g. Warfarin, Lovenox) within 7 days prior to the planned date of surgery.
- •The participant has a history of fecal incontinence
- •The participant has had injection therapy, infrared laser treatment or rubber band ligation for treatment of hemorrhoids within 1 month of screening
- •The participant has co-morbidities which, in the opinion of the investigator, will not be appropriate for the study.
Arms & Interventions
EEA Hemorrhoid and Prolapse Stapling Set
Intervention: EEA Hemorrhoid and Prolapse Stapling Set (Device)
Endosurgery Proximate PPH03 Stapling Set
Intervention: Endosurgery Proximate PPH03 Stapling Set (Device)
Outcomes
Primary Outcomes
Intraoperative Bleeding
Time Frame: Day 0 - time of surgery
Number of subjects who require intervention to stop intraoperative bleeding The analysis is based on the per protocol analysis set. Subjects who were misrandomized for excluded from this analysis therefore, the population here will differ from the participant flow.
Secondary Outcomes
- Post Operative Pain - (PI-NIRS)(Day 0 minus 60 (baseline), Day 0 (discharge), Day 0 plus 7, Day 0 plus 30, Day 0 plus 90, Day 0 plus 180)
- Post-Operative Pain (Analgesic Intake)(Day 0, 1 week, 2 week, 1 month, 3 month, 6 month)
- Overall Quality of Life - General Health Score(Day 0 minus 60, 1 week, 1 month, 3 months, 6 months)
- Location of the Staple Line(Day 0)
- Length of Stay(Day 0 time of discharge minus time of admission)
- Operative Room (OR) Time(Day 0)
